Patents Assigned to Administrators of the Tulane Educational Fund
-
Patent number: 8853452Abstract: Compounds and their syntheses are disclosed herein. Compositions and pharmaceutical compositions comprising a compound are also described, and include compositions also comprising liposomes. Methods for the treatment of cancer in animals comprising administering a compound or a composition comprising a compound are also described.Type: GrantFiled: February 9, 2010Date of Patent: October 7, 2014Assignee: The Administrators of the Tulane Educational FundInventors: Barbara S. Beckman, Maryam Foroozesh, Jiawang Liu
-
Publication number: 20140295472Abstract: A device utilizing agglutination and its method of use to diagnose diseases or conditions. The diagnostic device may comprise a substrate having pores, an agglutination zone, and a test readout zone wherein said agglutination zone is functionalized with an agglutinating agent to cause agglutination of the sample.Type: ApplicationFiled: November 13, 2012Publication date: October 2, 2014Applicant: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUNDInventors: Sergey S. Shevkoplyas, Xiaoxi Yang, Julie Kanter Washko, Nathaniel Zane Piety
-
Patent number: 8846848Abstract: Provided are monodisperse synthetic dendrimer calibrants for mass spectrometry. The calibrants are distinguished by their relative ease and rapidity of synthesis, comparatively low cost, long shelf life, high purity, and amenability to batch synthesis as mixtures. The latter characteristic enables parallel preparation of higher molecular weight compounds displaying useful distributions of discrete molecular weights, thereby providing multi-point mass spectrometry calibration standards. Methods of making and using said calibrants are also provided.Type: GrantFiled: February 3, 2010Date of Patent: September 30, 2014Assignee: The Administrators of the Tulane Educational FundInventor: Scott M. Grayson
-
Publication number: 20140271650Abstract: Immunogenic influenza hemagglutinin-derived peptide conjugates described herein induce a specific therapeutic antibody response against influenza virus. The immunogenic peptide conjugates comprise a segment from the fusion initiation region (FIR) domain of an influenza hemagglutinin protein conjugated to an immunogenic carrier protein, such as keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA), an influenza hemagglutinin (HA) protein (i.e., full length HA), and the like. The immunogenic peptide conjugates described herein can be utilized to treat or prevent influenza infection and to prepare influenza-specific therapeutic antibodies that interfere with influenza virus-host cell membrane fusion. The peptide conjugates can be formulated in pharmaceutical compositions useful for broad spectrum treatment or prevention of influenza infections.Type: ApplicationFiled: March 14, 2013Publication date: September 18, 2014Applicant: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUNDInventors: Robert Francis GARRY, Russell B. WILSON
-
Publication number: 20140271580Abstract: Immunoprotective primary mesenchymal stems cells (IP-MSC) which episomally express multiple immunoreactive polypeptides that specifically target a pathogen (e.g., an infectious species of virus, bacterium, or parasite) or toxin are described herein. The IP-MSC express two or more (e.g., 2 to about 100) immunoreactive polypeptides (e.g., full antibodies, single-chain antibodies (ScFV), Fab or F(ab)2 antibody fragments, diabodies, tribodies, and the like), and optionally one or more other immunomodulating polypeptides, e.g., a cytokine such as an interleukin (e.g., IL-2, IL-4, IL-6, IL-7, IL-9, and IL-12), an interferon (e.g., IFN?, IFN?, or IFN?), and the like, which can enhance the effectiveness of the immunoreactive polypeptides.Type: ApplicationFiled: March 14, 2013Publication date: September 18, 2014Applicant: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUNDInventor: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
-
Publication number: 20140243256Abstract: The present invention describes peptides which inhibit fusion of an arenavirus (e.g., Pichinde virus; PICV) with a host cell membrane. The arenavirus inhibiting (AVI) peptides described herein comprise a segment of the GP2 protein of an arenavirus. The AVI peptides are useful for inhibiting arenavirus-to-host cell membrane fusion and for treating arenavirus infections. In a particular embodiment, the arenavirus inhibiting peptide comprises a segment of PICV glycoprotein 2 (PICV GP2; SEQ ID NO: 1), Tamiami virus (TAMV) GP2 (SEQ ID NO: 14), or Lassa virus (LASV) GP2 (SEQ ID NO: 15). In particular, the segment is selected from a region of an arenavirus GP2 extending from the N-terminus into the first half of the FIR (i.e., from residues 1 through 105 of SEQ ID NO: 1, SEQ ID NO: 14, or SEQ ID NO: 15).Type: ApplicationFiled: March 14, 2013Publication date: August 28, 2014Applicant: The Administrators of the Tulane Educational FundInventors: Jennifer S. SPENCE, Robert F. GARRY
-
Publication number: 20140236170Abstract: Provided is a jaw tool formed from two separable units and which includes a fastening device that attaches the two units together when the jaw tool is in use and which may automatically separate the units after the device performs its function such as clamping and/or cutting. Also provided is a jaw tool having a cutting blade wherein the contours of the device are shaped so that force is concentrated on the cutting bade when the device is closed. The jaw tool may be manufactured from a single injection molded-component that is used in duplicate to form the jaw tool. The jaw tool may be used in various applications in which it may be beneficial to simultaneously clamp and cut an object, such as various medical applications including vascular, gastrointestinal, respiratory, and placental.Type: ApplicationFiled: March 21, 2012Publication date: August 21, 2014Applicant: The Administrators of the Tulane Educational FundInventors: William Kethman, Dann Schwartz, Steve Allen Franseen
-
Patent number: 8802106Abstract: The present invention provides an isolated peptide having an amino acid residue sequence that comprises at least one human cytomegalovirus glycoprotein B (HCMV-gB) sequence segment, each HCMV-gB sequence segment consisting of at least 8 and not more than 60 consecutive amino acid residues from residues 146 to 315, residues 476 to 494 of SEQ ID NO: 1, or from a sequence variant of residues 146 to 315 or 476 to 494 of SEQ ID NO: 1 that has at least 70% sequence identity thereto. The peptides of the invention are useful for treating, preventing, or inhibiting a herpesvirus (e.g., Herpes Simplex Virus-1, Human Cytomegalovirus, and the like) infection in a subject.Type: GrantFiled: October 29, 2010Date of Patent: August 12, 2014Assignee: The Administrators of the Tulane Educational FundInventors: Lilia I. Melnik, Robert F. Garry, Cindy A. Morris
-
Publication number: 20140206912Abstract: An underground reactor for creating hydrocarbons and chemicals from organic material preferably includes a heat recovery device. Some embodiments of the present invention include at least one tube that injects biomass underground and at least one second tube that collects reacted biomass on the surface. Further tubes are also disclosed for the ability to control temperature and pressure and collect minerals and carbon dioxide. Methods for utilizing the reactor are additionally provided. Further embodiments include methods of using the reactor such as, for example, methods of creating fuel from algae and methods of using the minerals and carbon dioxide as food for an algae farm that will be used as biomass for the reactor.Type: ApplicationFiled: May 3, 2012Publication date: July 24, 2014Applicant: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUNDInventor: Brandon Iglesias
-
Publication number: 20140194347Abstract: The present invention provides peptides, peptide analogs, peptide derivatives and pharmaceutical compositions useful for treating or preventing influenza infections or preventing the person-to-person transmission of an influenza infection. A peptide of the invention comprises an influenza virus-cell fusion inhibiting portion of the fusion initiation region (FIR) of a wild-type influenza hemagglutinin 2 protein or a variant thereof. In a preferred embodiment, a peptide of the invention consists of 8 to 40 consecutive amino acid residues a portion of a wild-type influenza hemagglutinin 2 protein or a variant thereof, the portion of the protein comprising the FIR of the protein and up to five amino acid residues on the amino-terminal and carboxy-terminal sides of the FIR.Type: ApplicationFiled: December 10, 2013Publication date: July 10, 2014Applicants: Autoimmune Technologies, LLC, The Administrators of the Tulane Educational FundInventors: Robert F. GARRY, Russell B. WILSON
-
Publication number: 20140178422Abstract: Episomally transfected primary mesenchymal stem cells (MSC) express a polypeptide consisting of an antigenic polypeptide (e.g., one or more polypeptides) relating to a pathogen (e.g., one or more virus, bacterium, or parasite). The antigenic polypeptide can have the amino acid sequence of a natural polypeptide from the pathogen or an amino acid sequence differing from the natural sequence by one or more conservative amino acid substitutions. Uses and method for treating or preventing infections with episomally transfected primary MSC also are described.Type: ApplicationFiled: November 15, 2013Publication date: June 26, 2014Applicant: The Administrators of the Tulane Educational FundInventors: Suzanne L. Tomchuck, Elizabeth B. Norton, Robert F. Garry, Bruce Bunnell, John D. Clements
-
Publication number: 20140166575Abstract: A method for cleaning an oil spill in a marine environment includes forming a particle-stabilized emulsion containing seawater, carbon black and at least one oil spill component and allowing the at least one oil spill component to degrade, thereby removing said component from the marine environment. Carbon black can be added to an oil-seawater mixture to form a stabilized emulsion containing at least one oil spill component and the oil spill component allowed to degrade, thereby removing the at least one oil spill component from the oil spill. Also disclosed is an emulsion that includes one or more oil spill components, seawater and carbon black particles.Type: ApplicationFiled: July 10, 2012Publication date: June 19, 2014Applicants: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, CABOT CORPORATIONInventors: Arijit Bose, Vijay T. John, Ani Tzankova Nikova
-
Patent number: 8716436Abstract: The invention relates to cyclic peptide agonists that bind to the mu (morphine) opioid receptor and their use in the treatment of acute and/or chronic pain. Embodiments of the invention are directed to cyclic pentapeptide and hexapeptide analogs of endomorphin that have (i) a carboxy-terminal extension with an amidated hydrophilic amino acid and (ii) a substitution in amino acid position 2. These peptide analogs exhibit decreased tolerance relative to morphine, increased solubility compared to similar tetrapeptide analogs, while maintaining favorable or improved therapeutic ratios of analgesia to side effects.Type: GrantFiled: May 22, 2012Date of Patent: May 6, 2014Assignees: The Administrators of the Tulane Educational Fund, U.S. Department of Veterans AffairsInventors: James E. Zadina, Laszlo Hackler
-
Publication number: 20140080115Abstract: A device for monitoring particulates includes a means for correlating measurements of pressure across at least one filter, flow rate of a sample through the filter, or a combination thereof to the properties of particulates in a solution. More particularly, the device can be used for monitoring particulates in a reacting system to provide signals to the user or control input to the reacting system to alter the course of the reaction according to a desired path.Type: ApplicationFiled: February 14, 2012Publication date: March 20, 2014Applicant: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUNDInventor: Wayne F. Reed
-
Publication number: 20140046105Abstract: An underground reactor for creating hydrocarbons and chemicals from organic material can include a heat recovery device. Some embodiments of the present disclosure include at least one tube that injects biomass underground and at least one second tube that collects reacted biomass on the surface. Further tubes are also disclosed for the ability to control temperature and pressure and collect minerals and carbon dioxide. In another embodiment, a super-critical fluid is injected into the underground reactor. Methods for utilizing the reactor are additionally provided. Further embodiments include methods of using the reactor such as, for example, methods of creating fuel from algae and methods of using the minerals and carbon dioxide as food for an algae farm that will be used as biomass for the reactor.Type: ApplicationFiled: August 9, 2013Publication date: February 13, 2014Applicant: The Administrators of the Tulane Educational FundInventor: Brandon J. Iglesias
-
Publication number: 20140045752Abstract: Multicomponent compositions and methods of use thereof are disclosed herein. Some embodiments of the present invention include multicomponent compositions comprising a first component and a second component, where the first component comprises a notch influencing molecule and the second component comprises a GPCR targeted molecule. Kits comprising the multicomponent composition are also disclosed. Methods for providing the multicomponent composition to one or more cells are additionally provided. Further embodiments include methods of using the multicomponent composition such as, for example, methods of administering the multicomponent composition and method of treating organisms (such as mammals) using the multicomponent composition.Type: ApplicationFiled: February 16, 2012Publication date: February 13, 2014Applicant: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUNDInventors: David H. Coy, Linchun Sun
-
Publication number: 20140045743Abstract: The present invention provides compositions and methods for treating a coronavirus infection. A method embodiment comprises administering a polypeptide (preferably in a biocompatible pharmaceutical carrier) to a subject suffering from a coronavirus infection. The polypeptide comprises or consists of at least a portion of the fusion initiation region (FIR) of a coronavirus fusion protein. In some embodiments, the polypeptide comprises or consists of a sequence selected from SEQ ID NO: 2, 22, 23, 24, and 25 or an 8 to 40 contiguous amino acid residue portion thereof.Type: ApplicationFiled: August 8, 2013Publication date: February 13, 2014Applicants: Autoimmune Technologies, LLC, The Administrators of the Tulane Educational FundInventors: Robert F. GARRY, Russell B. WILSON, I
-
Patent number: 8637234Abstract: Methods and compositions are provided for the use of an envelope polypeptide or a functional variant thereof from a lentivirus that is not HIV-1 as a molecular scaffold for HIV-1 epitopes. The HIV-1 epitopes can be recognized by HIV-1 binding antibodies, HIV-1 neutralizing antibodies and/or CD4-induced antibodies. Thus, methods are provided for detecting HIV-1 binding antibodies in a subject infected with HTV-1. Further provided are methods to determine an epitope for an HIV-1 binding antibody; methods to assay for an HIV-1 binding antibody; methods to identify a soluble CD4 mimic; methods to neutralize an non-HIV-1 virus; diagnostic assays to monitor HIV disease in a subject or to monitor the subject's response to immunization by a HIV vaccine; and methods to alter the neutralization potential of an HIV-1 derived CD4-induced antibody. Chimeric polypeptides, chimeric polynucleotides, kits, cells and viruses are also provided.Type: GrantFiled: April 8, 2005Date of Patent: January 28, 2014Assignees: UAB Research Foundation, The Administrators of Tulane Educational Fund, The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: George M. Shaw, James E. Robinson, Frederic Bibollet-Ruche, Julie M. Decker, Beatrice H. Hahn, Peter D. Kwong
-
Publication number: 20140017336Abstract: It has now been discovered that arsenic induces herpes viruses latent in infected cells to reactivate to the lytic stage. Herpes viruses in the lytic stage activate anti-herpes virus anti viral agents. Co-administration of arsenic compounds and anti-herpes viral agents to a population of cells infected with a herpes virus results in the death of the cells and inhibits proliferation of the virus. The invention is therefore useful for reducing a subject's population of cells infected with herpes viruses, particularly Epstein-Barr virus.Type: ApplicationFiled: April 6, 2012Publication date: January 16, 2014Applicant: ADMINISTRATORS OF THE TULANE EDUCATIONAL FUNDInventors: Mark D. Sides, Joseph A. Lasky
-
Publication number: 20140017298Abstract: The disclosed invention involves creating coatings on liposomes to increase stability within the body for drug delivery. The present invention includes a composition used for drug delivery, comprising liposomes and hydrophobically modified polysaccharides with alkyl groups, wherein the alkyl groups physically attach to and coat the liposomes.Type: ApplicationFiled: March 15, 2013Publication date: January 16, 2014Applicant: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUNDInventor: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND